Nanfang Hospital, Southern Medical University
南方医科大学南方医院
elsewhere's corpus does not cover Nanfang Hospital, Southern Medical University as a subject in its own right. The only mentions appear as a clinical collaborator of the microbiome drug developer Unknown (未知君), which partnered with the hospital on an intestinal microbiota capsule therapy for aGvHD as of 2020–2021 reporting . No entity card or article in the bundle profiles the hospital's history, scale, or institutional standing independently.
AI-generated — may contain errors, please verify.
Coverage
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
